Product Sales

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Product Sales

Product Sales

Net product sales consist of the following:

		Three Months Ended March 31,
(In millions)		2024		2023
EYLEA® HD	U.S.	$	200.0	$	—
EYLEA®	U.S.	1,201.6		1,433.8
Total EYLEA HD and EYLEA	U.S.	1,401.6		1,433.8
Libtayo®	U.S.	159.2		109.7
Libtayo	ROW(a)	104.7		67.2
Total Libtayo	Global	263.9		176.9
Praluent®	U.S.	70.0		40.2
Evkeeza®	U.S.	24.8		14.9
Inmazeb®	Global	1.0		2.2
		$	1,761.3	$	1,668.0
(a) Rest of world ("ROW")

As of March 31, 2024 and December 31, 2023, the Company had $3.739 billion and $3.888 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three months ended March 31, 2024 and 2023. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

	Three Months Ended March 31,
	2024		2023
Besse Medical, a subsidiary of Cencora, Inc.	51	%	52	%
McKesson Corporation	24	%	25	%